Newbury Pharmaceuticals announced the Marketing Authorization (MA) of Lapatinib Newbury 250 mg film-coated tablets in Sweden as the first country in a Scandinavian registration procedure. Approvals in Norway and Denmark are expected to follow upon finalized national reviews. Lapatinib is a targeted cancer drug, also known by its brand name Tyverb, that is used to treat certain types of breast cancer, where tumors overexpress HER2.

Newbury currently has licensed ten (10) products within oncology and plan to offer treatment options for both solid and hematological malignancies (e.g. breast cancer, myeloma, leukemia, prostate cancer and thyroid cancer).